Epidemiology, pathology and treatment of non-follicular indolent lymphomas

被引:7
作者
Landgren, Ola [1 ]
Tilly, Herve [2 ]
机构
[1] NCI, Natl Inst Hlth, Bethesda, MD 20892 USA
[2] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France
基金
美国国家卫生研究院;
关键词
non-Hodgkin lymphoma; non-follicular lymphoma; indolent lymphoma;
D O I
10.1080/10428190802311425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-follicular indolent subtypes of non-Hodgkin lymphoma (NHL), which include chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL) and marginal zone lymphomas (MZL), are a diverse group of disorders with different presenting features, behaviour patterns and treatment outcomes. Current knowledge of these subtypes is largely based on retrospective analyses. A precise diagnosis can be difficult to achieve, and specific diagnostic criteria are needed to more precisely define some of the rarer indolent tumors, such as nodal and splenic MZLs. Although some subtypes of NHL have a prolonged indolent course, with a good prognosis (e.g. SLL), others (e.g. nodal and splenic MZLs) can rapidly evolve into more aggressive subtypes. In asymptomatic patients, treatment may be deferred until the disease progresses and the patient becomes symptomatic. Universally accepted therapeutic guidelines do not exist, however, and carefully designed, prospective clinical studies are needed to further assess optimal therapeutic approaches for these indolent NHLs.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 65 条
[1]   Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course [J].
Algara, P ;
Mateo, MS ;
Sanchez-Beato, M ;
Mollejo, M ;
Navas, IC ;
Romero, L ;
Solé, F ;
Salido, M ;
Florensa, L ;
Martínez, P ;
Campo, E ;
Piris, MA .
BLOOD, 2002, 99 (04) :1299-1304
[2]   Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles [J].
Arcaini, L ;
Paulli, M ;
Boveri, E ;
Vallisa, D ;
Bernuzzi, P ;
Orlandi, E ;
Incardona, P ;
Brusamolino, E ;
Passamonti, F ;
Burcheri, S ;
Schena, C ;
Pascutto, C ;
Cavanna, L ;
Margrini, U ;
Lazzarino, M .
CANCER, 2004, 100 (01) :107-115
[3]  
Arcaini L, 2003, HAEMATOLOGICA, V88, P80
[4]   Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease [J].
Arcaini, Luca ;
Paulli, Marco ;
Burcheri, Sara ;
Rossi, Andrea ;
Spina, Michele ;
Passamonti, Francesco ;
Lucioni, Marco ;
Motta, Teresio ;
Canzonieri, Vincenzo ;
Montanari, Mauro ;
Bonoldi, Emanuela ;
Gallamini, Andrea ;
Uziel, Lilj ;
Crugnola, Monica ;
Ramponi, Antonio ;
Montanari, Francesca ;
Pascutto, Cristiana ;
Morra, Enrica ;
Lazzarino, Mario .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (02) :301-304
[5]   Splenic marginal zone lymphoma: a prognostic model for clinical use [J].
Arcaini, Luca ;
Lazzarino, Mario ;
Colombo, Nora ;
Burcheri, Sara ;
Boveri, Emanuela ;
Paulli, Marco ;
Morra, Enrica ;
Gambacorta, Marcello ;
Cortelazzo, Sergio ;
Tucci, Alessandra ;
Ungari, Marco ;
Ambrosetti, Achille ;
Menestrina, Fabio ;
Orsucci, Lorella ;
Novero, Domenico ;
Pulsoni, Alessandro ;
Frezzato, Maurizio ;
Gaidano, Gianluca ;
Vallisa, Daniele ;
Minardi, Viviana ;
Tripodo, Claudio ;
Callea, Vincenzo ;
Baldini, Luca ;
Merli, Francesco ;
Federico, Massimo ;
Franco, Vito ;
Iannitto, Emilio .
BLOOD, 2006, 107 (12) :4643-4649
[6]   Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes [J].
Audouin, J ;
Le Tourneau, A ;
Molina, T ;
Camilleri-Broët, S ;
Adida, C ;
Comperat, E ;
Benattar, L ;
Delmer, A ;
Devidas, A ;
Rio, B ;
Diebold, J .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) :404-412
[7]   Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients [J].
Berger, F ;
Felman, P ;
Thieblemont, C ;
Pradier, T ;
Baseggio, L ;
Bryon, PA ;
Salles, G ;
Callet-Bauchu, E ;
Coiffier, B .
BLOOD, 2000, 95 (06) :1950-1956
[8]  
BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO
[9]  
2-V
[10]   Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations [J].
Camacho, FI ;
Algara, P ;
Rodríguez, A ;
Ruíz-Ballesteros, E ;
Mollejo, M ;
Martínez, N ;
Martínez-Climent, JA ;
González, M ;
Mateo, M ;
Caleo, A ;
Sánchez-Beato, M ;
Menárguez, J ;
García-Conde, J ;
Solé, F ;
Campo, E ;
Piris, MA .
BLOOD, 2003, 101 (10) :4042-4046